Tandem Diabetes Care financials
$16.57+0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.01B | $940.2M | $747.7M | $801.2M | $702.8M | $498.8M | $362.3M | $183.9M | $107.6M | $84.2M |
| Gross profit | $546.0M | $489.6M | $367.7M | $413.0M | $376.2M | $260.5M | $194.2M | $89.8M | $44.1M | $23.6M |
| Gross margin | 53.8% | 52.1% | 49.2% | 51.5% | 53.5% | 52.2% | 53.6% | 48.9% | 41.0% | 28.0% |
| Operating income | -$187.3M | -$99.1M | -$233.2M | -$92.8M | $22.7M | -$8.0M | -$16.7M | -$44.6M | -$62.9M | -$78.1M |
| Net income | -$204.7M | -$96.0M | -$222.6M | -$94.6M | $15.6M | -$34.4M | -$24.8M | -$122.6M | -$73.0M | -$83.4M |
| Net margin | −20.2% | −10.2% | −29.8% | −11.8% | 2.2% | −6.9% | −6.8% | −66.7% | −67.9% | −99.0% |
| Diluted EPS | $-3.04 | $-1.47 | $-3.43 | $-1.47 | $0.24 | $-0.56 | $-0.42 | $-2.55 | $-12.87 | $-27.30 |
| EBITDA | -$74.4M | -$82.5M | -$138.8M | -$47.5M | $36.5M | $2.5M | -$10.7M | -$38.8M | -$56.1M | -$72.6M |
| Operating cash flow | -$9.7M | $24.2M | -$31.8M | $50.5M | $111.4M | $24.7M | $41.9M | -$8.3M | -$66.1M | -$61.2M |
| Free cash flow | -$108.3M | $5.0M | -$128.1M | -$9.4M | $97.2M | -$2.7M | $22.4M | -$11.3M | -$71.9M | -$70.1M |
| Diluted shares | 67.3M | 65.5M | 65.0M | 64.1M | 64.3M | 61.0M | 58.5M | 48.1M | 5.7M | 3.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $90.6M | $69.2M | $58.9M | $172.5M | $71.2M | $94.6M |
| Short-term investments | $202.0M | $369.1M | $409.0M | $444.4M | $552.6M | $390.3M |
| Total debt | $310.0M | $348.9M | $285.0M | $283.2M | $281.5M | $217.2M |
| Total assets | $881.1M | $967.7M | $952.7M | $1.05B | $905.1M | $716.4M |
| Total liabilities | $725.9M | $704.6M | $639.0M | $612.8M | $472.0M | $350.1M |
| Shareholders' equity | $155.2M | $263.1M | $313.6M | $439.9M | $433.1M | $366.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology